Gunnar Staaf – Chief Executive Officer
Gunnar is an economist by training from the University of Reading, UK and holds an MBA from Warwick Business School, UK. Gunnar has over 15 years of senior commercial and executive pharmaceutical experience ranging from large pharmaceutical companies (Eli Lilly & Novartis), mid-tier companies (Astellas) to small biotech companies (Serentis & Avantium Pharma). At Astellas, Gunnar held the position of European Brand Director, at Serentis he was the Commercial Director, and at Avantium Pharma, Gunnar held the position of Chief Executive Officer.

Marcel Hoffmann – Chief Scientific Officer
Marcel holds a Masters degree in Biology and Biochemistry from the University of Leiden and received his Ph.D. in molecular biology and biochemistry from the Free University, Amsterdam, The Netherlands. During his academic career he has published over 15 peer-reviewed publications. Prior to Avantium Pharma, Marcel was heading up the pharmacology department of Galapagos. In this role he contributed to six patent applications and two publications. In 2006 Marcel joined Avantium Pharma, now Crystallics, as Director, responsible for the internal development projects. Since January 2008 he has been part of the Avantium Pharma management team as Vice President Pharmaceutical Development and in April 2011, Marcel was promoted to Chief Scientific Officer of Crystallics.

Stephanie Mulder – Team Leader Operations
Stephanie holds a bachelor and masters degree in chemistry from the Université du Maine-Le Mans-Laval, France and received her PhD from the Université Pierre et Marie Curie, Paris, France. Immediately after obtaining her PhD, Stephanie joined Avantium Pharma, now Crystallics, and has fulfilled various roles within the company including research associate, project leader and senior project leader, before she was promoted to team leader, the role she currently fulfills. As such, Stephanie is responsible for the operational team of Crystallics.